Loading stock data…
Journey Medical Corporation (DERM)
$7.91+0.05 (+0.64%)
Market OpenUpdated 2:41 PM EDT
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Journey Medical Corporation in the Healthcare sector is trading at $7.97 with a market capitalization of $167M. Wall Street consensus targets $13.75 (4 analysts), implying a +72.5% move over the next 12 months. The stock is currently 17% below its 52-week high of $9.55, remaining 14.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +72.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.96M↓ | $16.08M↓ | $17.63M↑ | $15.01M↑ | $13.14M |
| Gross Profit | $9.74M↓ | $10.64M↓ | $11.88M↑ | $10.07M↑ | $8.35M |
| Operating Income | -$1.49M↓ | -$443,000↑ | -$1.53M↑ | -$2.88M↑ | -$3.32M |
| Net Income | -$2.23M↓ | -$1.25M↑ | -$2.31M↑ | -$3.80M↑ | -$4.07M |
Peer Comparison
JNJUNHPFE
Fundamentals
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed produc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$166.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.03
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.10%
Volume
Today's trading volume
90,937
Recent News
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
Journey Medical (DERM) Q2 2026 Earnings Call Transcript
Emrosi prescriptions hit 14,000 in July as payer coverage expands and margins improve.
Journey Medical Corp (DERM) (Q2 2026) Earnings Call Highlights: Emrosi Surges 20% Sequentially, ...
Journey Medical Corp (DERM) narrows net loss to $300K as Emrosi prescriptions hit all-time highs and payer access expands.
Journey Medical Corporation Q2 2026 Earnings Call Summary
Moby summary of Journey Medical Corporation's Q2 2026 earnings call
Fortress Biotech Q2 Earnings Call Highlights
Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief Executive Officer Claude Maraoui said the company generated positive EBITDA in the second quarter and